Sanofi Healthcare India has broken new ground with the approval of its biologic medicine, Dupixent® (dupilumab). It offers a ray of hope to adults with moderate-to-severe atopic dermatitis who have not been successful with topical prescription therapies or for whom these therapies aren’t recommended. In stark contrast to traditional treatments that suppress the immune system broadly, Dupixent® targets the underlying type 2 inflammation, thereby revolutionizing treatment approaches globally.
The atopic dermatitis treatment spectrum has been fraught with limited options for sufferers. This chronic skin disease causes severe itching, dryness, redness, and other uncomfortable symptoms. With Dupixent®’s approval in India, patients can now look forward to an alternative treatment that has shown significant improvements in disease signs, symptoms, and overall quality of life.
Developed through a global collaboration between Sanofi and Regeneron, Dupixent® has proven successful in over 60 countries. Having treated more than 600,000 patients worldwide, it now prepares to serve the Indian demographic afflicted by moderate-to-severe atopic dermatitis.
Author
-
Similar Posts
Pharmaceuticals JB Pharma Reduces Price of AZMARDA (Sacubitril-Valsartan®) by Nearly 50%
Pharmaceuticals Ikris Pharma takes strides against breast cancer with the inspiring Ikris Run; uniting communities for awareness and action
Pharmaceuticals Zeal Specialty Pharmacy Credentialed in Record Time
